A large proportion of the cells of the human atherosclerotic plaque is assumed to be derived from medial smooth muscle cells. In contrast to these, the cells of the plaque have the capacity to accumulate lipid, and they also proliferate at a higher rate than medial cells. It has therefore been suggested that smooth muscle cells undergo a change of phenotype during atherogenesis, but there has been no evidence for such a change on the molecular level. We have now analyzed carotid artery plaques using a battery of antibodies against cell surface and cytoskeletal antigens, and found that most of the cells express the class II transplantation antigen (Ia antigen) HLA-DR. Also, the beta chain of HLA-DR was detected by immunoblotting of plaque extracts with the OKIal nmonoclonal antibody. HLA-DR is normally present on cells of the immune system, but only 60% of the DR-positive cells of the plaque reacted with monoclonal antibodies specific for macrophages and lymphocytes. Many of the remaining DR-positive cells contained the muscle-specific intermediate filament protein, desmin. This indicates that smooth muscle cells of atherosclerotic plaques express DR antigen. In contrast, very few DRpositive cells were found in normal human arteries. This suggests that expression of class II antigen is part of a phenotypic change in smooth muscle cells in atherosclerosis.
Introduction
The major histocompatibility complex (MHC)' encodes several groups of proteins. Among these, class I transplantation antigens (in humans, the HLA-ABC system) are expressed on almost all nucleated cells (1) . In contrast, class II transplantation antigens (in humans, HLA-DR, HLA-DC, and HLA-SB, collectively often referred to as Ia antigens) are generally limited to cells involved in the immune system (2, 3) . These glycoproteins, when present in the plasma membrane of macrophages, participate in the presentation of foreign antigens to T cells (2, 4) . Other cells, such as endothelial cells and Langerhans' they may also serve as antigen-presenting cells (5, 6, 11) . Finally, class II antigens can be expressed on several other cell types under certain conditions. Intestinal, urinary, and other epithelia may express class II antigens, as well as several tumor cells (9, (13) (14) (15) (16) (17) (18) (19) (20) (21) . The functional significance of this phenomenon is unknown, although it has been suggested that these cells might also present antigens to T cells (22) .
In this study, we have detected class II antigen on smooth muscle cells in human atherosclerotic plaques with the use of antibodies to HLA-DR. The majority of the cells in surgical biopsies of carotid artery plaques expressed HLA-DR antigen. Only 60% of the cells were positive for markers for macrophages or leukocytes. Among the remaining DR-positive cells, many had desmin-containing intermediate filaments, and could therefore be identified as smooth muscle cells (23) (24) (25) . In contrast, no smooth muscle cells were HLA-DR positive in biopsies of normal human arteries. These data suggest that smooth muscle cells, which do not normally express class II antigens, are induced to express HLA-DR in atherosclerosis.
Methods
Arterial tissue. Atherosclerotic arterial biopsies were obtained from 16 patients with atherosclerosis of the internal carotid arteries. The patients were between 48 and 70 yr old, and did not have any other systemic diseases. They were operated on due to cerebral manifestations, usually transitory ischemic attacks, and fibrofatty plaques were obtained during thromboendarterectomy. Nonatherosclerotic arterial biopsies were obtained from the aortic base during coronary bypass surgery, and from the uterine artery during hysterectomy. Coronary bypass patients (n = 5) were between 53 and 69 yr old, and hysterectomy patients (n = 4) were between 26 and 48 yr old. All biopsies were immersed in ice-cold Hanks' balanced salt solution (HBSS), were transported to the laboratory, and processed further within 20 Rabbit antibodies to vimentin were raised in the following way. Vimentin was isolated from cultured bovine endothelial cells by preparative electrophoresis (31) , and rabbits were immunized three times with Freund's incomplete adjuvant. A hyperimmune serum was obtained after a booster injection, and its specificity was tested by electroblotting and immunocytochemistry.
Antibodies to desmin were raised in rabbits immunized with chicken gizzard desmin (32) . Specific antibodies were isolated from the antiserum by affinity chromatography as described (33) .
Immunofluorescence. Parts of the specimens from all patients were embedded in OCT embedding medium (Miles Laboratories, Inc., Elkhart, IL) and snap-frozen in n-hexane that was chilled with liquid nitrogen. 8-Am sections were fixed for 5 min in 95% ethanol, rinsed in phosphate-buffered saline (PBS, 150 mM NaCl, 20 mM phosphate buffer, pH 7.2), and preincubated with 2% normal serum, immediately followed by incubations with either mouse or rat monoclonal antibodies or rabbit polyclonal antibodies, which were all diluted in PBS with 4% bovine serum albumin (Sigma Chemical Co., St. Louis, MO). After being rinsed repeatedly with PBS, the sections were incubated in a similar fashion with biotinylated antibodies against mouse, rat, and rabbit IgG, respectively. They are then rinsed again, incubated with fluorescein isothiocyanate (FITC)-labeled avidin (Vector Laboratories) at 25 ug/ml, rinsed, and mounted in PBS with 10% glycerol. The sections were examined in a fluorescence microscope (Ultraphot III; Carl Zeiss, Oberkochen, West Germany), equipped with an HBO50 lamp, epi-illumination, dielectric interference filters, and 20 X and 40 X fluorescence objectives. All antibodies were used at optimal dilutions determined by chessboard titrations. The following controls were performed: omission of (a) the first or (b) the second antibody, use of preimmune serum instead of (c) first or (d) second antibody, (e) use of an unrelated antibody instead of first antibody, or (f) use of an unrelated, biotinylated antibody instead of the second antibody.
A control for binding of the Fc part of specific antibodies to the Fc receptor of cells in the sections was made in the following way. Immune complexes were made by incubating human serum albumin with anti-albumin antibodies (Dako) at a molar ratio of 1:1, for 3 h at 37°C. After being washed, they were diluted in PBS (1:2, 1:20, and 1: 200) and incubated on sections. The sections were then incubated with OKIal, biotinylated anti-mouse IgG, and FITC-avidin.
The number of immunoreactive cells was determined in the following way. At a magnification of 200 (20 X objective), eight microscopic fields were randomly chosen in the plaques. After counting, the sections were demounted and counterstained with Mayer's hemalun. Fields that had been counted were identified, and all nuclei were counted. Between 100 and 200 cells were present in each field.
In double-staining immunofluorescence experiments, sections were first incubated with a monoclonal antibody, followed by biotinylated anti-mouse IgG and FITC-avidin as described above. They were then exposed to rabbit-anti-Factor VIII, rabbit-anti-vimentin, or rabbit-antidesmin antibodies followed by rhodamine-conjugated swine-anti-rabbit IgG. In controls, either one or both of the primary antibodies were omitted or substituted by preimmune IgG.
Histochemistry. Fresh cryostat sections were incubated for 40 min in a substrate solution for detection of alpha-naphtyl acetate esterase as described (34) , and then counterstained with Mayer's hemalun.
Isolation of cells. Parts of the arterial biopsies were immediately cut into small pieces with fine forceps, washed twice in HBSS by lowspeed centrifugation, and digested for 60 min at 37°C on a shaking water bath with a modification of the method described by Haley et al. (35) . Digestion was with 900 IU/ml collagenase (Cl. histolyticumcollagenase type I, Sigma Chemical Co.), 1.0 mg/ml soybean trypsin inhibitor (Sigma), and 5.0 mg/ml bovine serum albumin in calciumand magnesium-free HBSS. The digested material was filtered through a 150-Mm mesh nylon filter, and cells were harvested by low-speed centrifugation. They were washed twice with HBSS, and subjected to the receptor assays described below. All glassware used with the cells were siliconized.
Fc receptor assay. This assay was performed essentially as described by Bianco et al. (36) . In brief, a washed concentrate of sheep erythrocytes was incubated with anti-sheep erythrocyte antiserum (Statens Bakteriologiska Laboratorium, Stockholm, Sweden) for 60 min at room temperature. The coated erythrocytes were washed twice with PBS and suspended to a concentration of 1%. 500 Al of a suspension of the isolated arterial cells (10-20 X I04 cells/ml), 200 Al fetal bovine serum (FBS, Flow Laboratories, Irvine, Scotland), and 10 drops of the erythrocyte suspension were mixed by centrifugation at 40 g for 5 min, and the loose pellet was incubated for 45 min at 370C. The cells were resuspended, and drops of cells were air-dried onto microscopic slides and fixed with ice-cold acetone. Cells were counterstained with 0.1% Evans blue in PBS to quench erythrocyte autofluorescence, and were then stained with OKIal using the biotin-avidin immunofluorescent system as described above.
E receptor assay. T cell-specific E receptors (sheep erythrocyte receptors) were demonstrated as described (37) . Briefly, AET-(32-aminoethylisothiouronium-hydrobromide) treated sheep erythrocytes were suspended to a concentration of 10%, and eight drops of this suspension were incubated for 5 min at 370C with 500 Ml of a suspension of isolated arterial cells and 200 Ml FBS. The mixture was then centrifugated at 40 g for 5 min, and incubated as a loose pellet at +40C overnight. The cells were resuspended, and HLA-DR-positive cells were detected with OKIal and biotin-avidin-immunofluorescence as described above.
Characterization ofHLA-DR expression. Isolated plaque cells were divided into four portions. One was immediately fixed with acetone and stained for HLA-DR as described. The second portion was treated for 30 min at 370C with 5 mM EDTA, 320 mM sucrose, 5 mM PBS, pH 7.4, to remove extrinsic plasma membrane proteins (38). After being washed in HBSS, the cells were analyzed for HLA-DR expression by immunofluorescence. The third portion of cells was incubated with 0.25% trypsin in PBS for 30 min at 370C, washed with HBSS with 20% FBS, and analyzed for HLA-DR. The fourth portion was also treated with trypsin as described and washed with FBS-containing HBSS, but then incubated for 3 h at 37°C in HBSS-FBS before staining for HLA-DR. Some of the slides from the latter group were doublestained for HLA-DR and desmin as described above.
Electrophoresis and immunoblotting. 5-mm3 pieces of human carotid artery atherosclerotic plaques were homogenized in SDS sample buffer (39) with a Polytron homogenizer, and the proteins were separated by SDS-polyacrylamide gel electrophoresis using a Laemmli system with a 10% separating gel. Part of the gel was stained with Coomassie Brilliant Blue; the rest was used for electroblotting. Polypeptides were transferred to nitrocellulose paper at 60 V in a Tris-glycine buffer, pH 8.3, with 20%1 methanol (40). One part of the paper was used for antibody incubations, and the other was stained with Amido black. For antibody staining, the paper was preincubated for 5 h with 0.3% gelatin in TBS (Tris-buffered saline, 150 mM NaCl, 10 mM Tris-HCl, pH 7.4), followed by an 8-h incubation with OKIal at 1:100 in TBSgelatin. After being rinsed, the paper was incubated for 6 h with '25I-labeled rabbit-anti-mouse IgG, rinsed again, and exposed to Kodak Xomat-AR film (Eastman Kodak Co., Rochester, NY) for 3 d at -850C.
Results
Cell surface proteins were detected in human arterial tissue by immunofluorescence, using monoclonal antibodies to the cell surface protein, followed by biotinylated anti-mouse IgG and FITC-avidin. The class II transplantation antigen, HLA-DR, was detected with the monoclonal antibody OKIal, which reacts with a framework determinant common to all allelic forms of the human HLA-DR protein (26) . In the carotid plaques, many DR-positive cells were found immediately beneath the endothelium, but others were distributed throughout the fibrous cap and in the necrotic core of the plaque ( Figs. 1 and 2) . 69% of the cells in carotid atherosclerotic plaques contained HLA-DR antigen, and 37% of the cells in the nonatherosclerotic intima surrounding the plaque were HLA-DR positive (Table I) . Similarly, 73% of the cells in aortic atherosclerotic plaques obtained at autopsy were DR- The HLA-DR antigen is known to be present on monocytes, macrophages, B lymphocytes, and certain T lymphocytes, and such cells were therefore identified in the vessel wall with monoclonal antibodies to cell type-specific antigens. In the carotid artery plaques, 29% of all cells were identified as monocyte/macrophages positive for the antibody Anti-Leu-M3 (Table I) . Their Antibodies to desmin were therefore used as markers for smooth muscle cells. Double-staining experiments using rabbitanti-desmin and OKIal revealed that 26±6% (mean±SD) of the DR-positive cells in the plaque contained desmin (Fig. 4) . In contrast, there were no DR-positive, desmin-containing cells in the intima surrounding the plaque.
The cytoplasmic distribution of HLA-DR in the smooth muscle cells suggested that these cells synthesized the protein, but it could not be excluded that HLA-DR produced by other cells in the tissue might have adhered to the surface of muscle cells. A series of experiments was performed on isolated cells to answer this question (Fig. 5) . First, isolated plaque cells were treated with EDTA under low ionic strength. This removes extrinsic proteins from the plasma membrane (38) but did not reduce the number of DR-positive cells. This number could, however, be reduced drastically by trypsin treatment (Fig. 5) . When the cells were allowed to recover for 3 h after trypsinization, a large proportion of them regained DR-expression (Fig. 5) . 3 h after trypsin treatment, 53.7% of the DR-positive cells were also desmin-positive in doublestaining immunofluorescence. Taken together, these data show that the HLA-DR reactive antigen is actively expressed as an integral membrane protein of a large proportion of plaque cells, many of which are smooth muscle cells. demonstrates HLA-DR expression on a desmin-positive smooth muscle cell in a carotid plaque (magnification of 1,900).
To identify the polypeptide in the plaque which reacted with the anti-HLA-DR antibody, we subjected extracts of homogenized plaques to SDS-polyacrylamide electrophoresis, followed by electroblotting and incubation with OKIal. The antibody reacted with a polypeptide of -28,000 Mr, corresponding to the beta chain of the HLA-DR protein (27, 46) (Fig. 6) . The alpha chain of HLA-DR was expressed by the 15 (2, 4) . They may, however, also be expressed in several epithelial cells (8, 9, 13-17, 19, 20, 22, 51) and endothelial cells (5, 6, 10-12). Cultured vascular endothelium starts to express HLA-DR when stimulated by lectins or immune interferon (10) (11) (12) . This shows that the expression of class II antigens may be subjected to regulation. It is now important to identify the stimuli that induce HLA-DR expression on smooth muscle cells, and to determine which of these are active in the arterial intima during the development of atherosclerosis.
The only known function of class II antigens is to participate in the recognition of foreign antigens by T cells (2, 4) . This reaction is followed by clonal proliferation of specific T cells (2) . This proliferation is probably induced by two growth regulators; interleukin 1, which is produced by the macrophage, and the T cell product interleukin 2 (2). In analogy, "aberrant" expression of Ia antigens by other cells might be related to antigen presentation and/or growth stimulation. Data from studies of human umbilical vein endothelium suggest that these cells can substitute for macrophages as antigen-presenting cells (5) . In recent studies of MRL mice, which develop an inherited autoimmune disease, Moyer and Reinisch (52) 
